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Introduction
A subdermal contraceptive implant is a single-rod, nonbio-
degradable implantable contraceptive that contains the pro-
gestin etonogestrel. The contraceptive efficacy of subdermal 
contraceptive implant was high, with zero pregnancies during 
treatment with subdermal contraceptive implant, resulting 
in a Pearl index of 0.0 (95% confidence interval, 0.0 to 0.2) 
[1]. It has been used widely throughout the world, providing 
contraceptive protection for up to 3 years when inserted sub-
dermally [2-4]. Etonogestrel, the active metabolite of desoges-
trel, is a progestin with a well-established safety and efficacy 
profile that is also used in a contraceptive etonogestrel/ethinyl 
estradiol vaginal ring (NuvaRing, Organon USA Inc., Roseland, 
NJ, USA) [2]. 
Attention should be paid to careful insertion and removal 
techniques. Because the rod is nonbiodegradable, subdermal 
contraceptive implant should be removed after the maximum 
duration of action or whenever desired. Subdermal contra-
ceptive implant insertion is more complex. Improper insertion 
of the device may result in migration of the subdermal con-
traceptive implant over 2 cm [2]. The subdermal contraceptive 
implant may not be placed in arm at all due to failed inser-
tion. When it occurs, women who received subdermal contra-
ceptive implantation can become pregnant and this may lead 
to contraception failure and pregnancy [5]. Also, removal of 
the subdermal contraceptive implant may be very difficult or 
impossible if the subdermal contraceptive implant is located 
at unexpected positions. Special procedures, including sur-
gery in the hospital, may be needed to remove the implant, 
if not properly placed. If the implant is not removed, then the 
effects of implant will continue for a longer period of time. 
Other problems related to insertion and removal include pain, 
irritation, swelling, bruising, scarring, infection, injury to the 
nerves or blood vessels, and breakage of the implant [6].
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We operate a transfer center for patients with difficult im-
plant removal, some implants have been found lying deeply in 
muscle due to faulty insertion technique or weight gain. Here 
we report a case of migrated implant into lung.
Case report
A 37-year-old woman, without medical/surgical history, had 
a radiopaque subdermal contraceptive implant (Nexplanon, 
Merck & Co., Whitehouse Station, NJ, USA) inserted in the 
left upper limb for contraception at a local clinic in 2014. The 
patients experienced irregular vaginal bleeding for two years 
after subdermal contraceptive implant and decision was made 
to remove the device. The subdermal contraceptive implant 
was not located by digital palpation or by ultrasound scanning 
of the insertion site. X-ray evaluation of both humerus anterior 
and posterior was conducted and radiopaque foreign body 
was not detected. In addition, the long bone upper extremity 
standing anterior posterior lateral X-ray was performed, and 
it showed that about 4 cm length rod-like material is seen at 
the left lower thoracic area (Fig. 1A). Under the impression of 
foreign body at lower thoracic area, A non-contrast-chest com-
puted tomography (CT) was performed, looking for a possible 
migration. It revealed that the foreign body was in left lower 
lobe of the lung (probably in subsegmental pulmonary artery 
branch in left posterior basal segment) (Fig. 1B). The patient 
did not experience symptoms including chest discomfort or 
dyspnea while having the subdermal contraceptive implant. Af-
ter consultations with cardiology and chest thoracic surgery de-
partment, the foreign body removal through intervention was 
considered initially at the division of cardiology, department of 
internal medicine. However, the foreign body was present in 
the lung parenchyme, and the decision was made to remove 
it through surgery at the department of chest thoracic surgery. 
The patient was admitted to cardiothoracic department. Under 
general anesthesia, the patient was positioned in the right de-
cubitus position during a surgery and a 6-cm minithoracotomy 
has performed at left intercostal space. Left lower lobe of lung 
was retracted using a long clamp and the site of foreign body 
was confirmed manually. Bovie cauterization was done to 
expose the foreign body and enucleation was performed im-
mediately afterward. A 24 Fr-standard chest tube was inserted 
and the surgery was completed (Fig. 2). The chest tube was 
removed on postoperative day 2. The patient was discharged 
from the hospital without complication. And further contracep-
tion plan was discussed at the outpatient clinic of the depart-
ment of obstetrics and gynecology.
Discussion
The subdermal contraceptive implant is a long-active proges-
togen-only contraceptive method that contains 68 mg etono-
gestrel [6]. Significant migrations (>2 cm) are uncommon, and 
primarily occur caudally looking to the insertion site. Another 
A  B
Fig. 1. (A) Long bone upper extremity standing anterior posterior lateral X-ray showing a linear opaque structure (arrow) in pulmonary 
hemi-right field. (B) Non-contrast chest computed tomography showing that the foreign body (arrow) was in left lower lobe (probably in 
subsegmental pulmonary artery branch in left posterior basal segment).
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side effects include deep insertion, fibrous adhesion and bro-
ken implant, the prevalence of the side effects are estimated 
to be 1.1% [7].
In our case, it is estimated that an inadvertent placement 
of the subdermal contraceptive implant into the basilic vein 
occurred during the initial procedure. The subdermal con-
traceptive implant migrated through the upper limb veins, 
stopping in the pulmonary artery branch in left posterior basal 
segment, then broke through the pulmonary artery branch 
and invaded the lung parenchyme. When the subdermal con-
traceptive implant dislocated in pulmonary artery, intervention 
could be a method to remove it [8], but in this case thoracot-
omy was done due to difficult access. In previous case, it was 
attempted endovascular retrieval by selective catherization of 
pulmonary artery, using a gooseneck loop snare. After failing 
many times, hybrid operating room-guided video-assisted 
thoracoscopic surgery was conducted for removal [9]. 
Instructions for insertion state that subdermal contraceptive 
implant should be placed subdermally at the inner side of the 
upper nondominant arm about 7 cm above the elbow crease 
in the groove between the biceps and the triceps. The needle 
of the subdermal contraceptive implant inserter is introduced 
in the above-mentioned space, directly under the skin. Be-
cause it is coated with barium sulphate, it is detactable on X-
ray or CT [10]. It is inserted in the subcutaneous plane on the 
medial aspect of the nondominant arm, 8 to 0 cm proximal 
to the medial epicondyle under local anesthesia and should 
be palpable throughout its use. Recommended removal is 
described in the product information, and is via a small sub-
cutaneous incision at the distal end of the palpable rod, with 
the rod manually pushed through the incision and grasped 
with forceps as it appears. Notably, no dissection is required. 
In the case of the rod not being palpable it is recommended 
that ultrasound, X-ray, CT or magnetic resonance imaging 
be used to locate and remove the rod [11]. Previous studies 
show when the implant is inserted deep into soft tissue, the 
ultrasound is highly effective in assisting in the removal of 
impalpable [12]. The majority of impalpable implants were 
removed under local anesthetic with ultrasound control. The 
ultrasound-guided blunt dissection, in conjunction with a 
22-g spinal needle to lift and stabilize the midpoint of the 
implant, has been shown to be the most effective technique 
of removing the implants [13].
Complications with insertion and removal of subdermal 
contraceptive implant are rare in the hands of medical profes-
sionals familiar with the techniques and device, and these 
procedures should only be undertaken by those with relevant 
training. 
In many cases, when the inserted implant is not palpable, 
it is located in muscle layer or soft tissue. Imaging studies 
including X-ray usually detect contraceptive implant placed 
subdermally in the upper arm but when the implant migrate 
form their initial implantation, an evaluation on lung and 
heart is necessary. Measuring serum etonogestrel level should 
considered among implant users. Also, all women should be 
informed and consent to disadvantages including device dis-
location, irregular vaginal bleeding, unexpected side effects 
inserting subdermal contraceptive implant.
A  B
Fig. 2. (A) Mini-thoracotomy was performed by a chest surgeon. Left lower lobe was retracted by lung clamp, then subdermal contracep-
tive implant (arrow) was exposure. (B) The 4-cm-sized subdermal contraceptive implant was removed. 
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